Lenvatinib plus pembrolizumab shows promise for metastatic kidney cancer

The results from the renal cell carcinoma (RCC) group of patients in a phase 1b/2 trial of a combination of lenvatinib plus pembrolizumab were presented at the 2018 American Society of Clinical Oncology (ASCO) annual meeting in Chicago this week. In this study, 30 patients with metastatic clear cell RCC were treated with oral lenvatinib […]

read more

Tyrosine kinase inhibitors for kidney cancer: Past, present and future

In his keynote lecture at the American Society for Clinical Oncology Genitourinary (ASCO GU) 2018 meeting in San Francisco this month, Dr Robert Motzer from Memorial Sloan Kettering Cancer Center in New York discussed the past, present and future of vascular endothelial growth factor (VEGF) tyrosine kinase inhibitors (TKIs) for the treatment of advanced/metastatic renal cell carcinoma […]

read more

Lenvatinib plus pembrolizumab combination designated a breakthrough therapy by the FDA

The US Food and Drug Administration (FDA) have granted Breakthrough Therapy Designation for the multiple receptor tyrosine kinase inhibitor, lenvatinib (Kisplyx) in combination with the anti-PD-1 therapy, pembrolizumab (Keytruda) for the treatment of patients with advanced and/or metastatic renal cell carcinoma (RCC). The breakthrough therapy designation speeds up the development and review of medicines that […]

read more

Sequencing of treatments for advanced kidney cancer remains uncertain

There are now a number of licensed drug options available for the treatment of advanced renal cell carcinoma (RCC). Many of them have data supporting their use as first- and second-line treatments. However, it is still not clear what sequence these drugs should be used in, especially as data coming out of clinical trials may […]

read more

Lenvatinib/everolimus combination approved by NICE for use in NHS England and Wales for advanced kidney cancer

Fantastic news for people with advanced kidney cancer: the lenvatinib (Kisplyx) plus everolimus (Afinitor) combination has been recommended by the National Institute for Health and Care Excellence (NICE) for use by the NHS in England and Wales for people with advanced renal cell carcinoma (RCC) that has been previously treated. This is the first combination of treatments to be […]

read more

The evolving management of advanced renal cell carcinoma

This article, published in UroToday this week, is a nice summary of the latest treatments available or in development for clear cell renal cell carcinoma and non-clear cell renal cell carcinoma. Read the article in UroToday here

read more

European Society of Medical Oncology (ESMO) highlights from the IKCC

The International Kidney Cancer Coalition (IKCC) had a booth at the European Society of Medical Oncology (ESMO) 2017 conference in Madrid last week. Please follow the link below to read the kidney cancer highlights from the conference. Read the kidney cancer highlights from ESMO on the IKCC website

read more

Lenvatinib plus pembrolizumab combination shows promise in advanced kidney cancer

Interim results from Study 111, a phase Ib/II clinical trial exploring the potential of a combination of lenvatinib (Kisplyx), a tyrosine kinase inhibitor (TKI), plus pembrolizumab (Keytruda), a PD-1 inhibitor, in patients with solid tumours, were presented at the European Society of Medical Oncology (ESMO) conference in Madrid, Spain this week. The results presented for […]

read more

European Commission approves Kisplyx (lenvatinib) for advanced kidney cancer

The European Commission has approved Kisplyx (lenvatinib) for the treatment of people with advanced renal cell carcinoma (RCC). Lenvatinib is a new, more potent tyrosine kinase inhibitor, that is given in combination with everolimus for the treatment of people with advanced RCC following the failure of one prior vascular endothelial growth factor (VEGF) targeted therapy. Lenvatinib […]

read more
Showing all 9 results
  TOP